Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2.

Solek, Julia; Chrzanowski, Jedrzej; Cieslak, Adrianna; Zielinska, Aleksandra; Piasecka, Dominika; Braun, Marcin; Sadej, Rafal; Romanska, Hanna M

Solek, Julia; Chrzanowski, Jedrzej; Cieslak, Adrianna; Zielinska, Aleksandra; Piasecka, Dominika; Braun, Marcin; Sadej, Rafal; Romanska, Hanna M.

Afiliación

Solek J; Department of Pathology, Chair of Oncology, Medical University of Lodz, 92-213 Lodz, Poland.
Chrzanowski J; Department of Biostatistics and Translational Medicine, Medical University of Lodz, 90-419 Lodz, Poland.
Cieslak A; Department of Biostatistics and Translational Medicine, Medical University of Lodz, 90-419 Lodz, Poland.
Zielinska A; Department of Biostatistics and Translational Medicine, Medical University of Lodz, 90-419 Lodz, Poland.
Piasecka D; Department of Pathology, Chair of Oncology, Medical University of Lodz, 92-213 Lodz, Poland.
Braun M; Department of Molecular Enzymology and Oncology, Intercollegiate Faculty of Biotechnology, Medical University of Gdansk, 80-210 Gdansk, Poland.
Sadej R; Department of Pathology, Chair of Oncology, Medical University of Lodz, 92-213 Lodz, Poland.
Romanska HM; Department of Molecular Enzymology and Oncology, Intercollegiate Faculty of Biotechnology, Medical University of Gdansk, 80-210 Gdansk, Poland.

Biomedicines ; 10(5)2022 May 03.

Article en En | MEDLINE | ID: mdl-35625798

Palabras clave

DCIS; HER2; recurrence; tumour immune microenvironment

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Idioma: En Revista: Biomedicines Año: 2022 Tipo del documento: Article País de afiliación: Polonia Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google